Table 1.

The Laboratory Data of Both Controls and Patients With Pelvic Inflammatory Disease (PID) Before and After They Received Treatmenta

Clinical variables	Controls (n = 70) Median (range)	Pretreated (n = 64) Median (range)	Posttreated (n = 64) Median (range)	P‐value UT/Cb	P‐value UT/Tc
YKL‐40 (ng/ml)	21.69	38.36	27.54	P = 0.001	P < 0.001
	(2.85–79.66)	(5.25–187.61)	(5.20–180.47)
CRP (mg/dl)	0.30 (0.02–1.65)	4.87 (0.30–24.60)	0.94 (0.30–11.30)	P < 0.001	P < 0.001
WBC (/mm3)	6,775	11,085	6,120	P < 0.001	P < 0.001
	(3,390–16,400)	(3,880–25,950)	(2,350–13,240)
Neutrophils (/mm3)	4,250	8,927	3,595	P < 0.001	P < 0.001
	(1,733–12,464)	(2,091–21,625)	(1,130–11,122)

CRP, C‐reactive protein; WBC, white blood cell; C, controls; UT, patients with PID before they received treatment; T, patients with PID after they received treatment.

^a P‐value < 0.05 was considered significant.

^bThe statistical difference was analyzed by Mann–Whitney U‐test.

^cThe statistical difference was analyzed by Wilcoxon signed‐ranks test.